Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04081-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Anna R Bopp und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center,…. Hauptthemen laut MEDLINE: Pyrimidines, Agammaglobulinaemia Tyrosine Kinase, Pyrazoles, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, NIDCR NIH HHS, American Cancer Society.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) is one of the most diagnosed malignancies globally, with a 5-year survival rate of only 40-50%. Current therapies are limited to aggressive chemoradiotherapy combinations and disfiguring resection. Recent research has demonstrated that inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib is an effective treatment for aggressive solid cancers. However, little is known about the effects of ibrutinib on aggressive HNSCC. We tested the efficacy of ibrutinib against HNSCC in vitro and in a metastatic, aggressive MOC2 orthotopic murine model and determined the underlying mechanisms. Ibrutinib decreased cancer cell growth in vitro, reduced tumor burden in vivo, decreased metastasis to the tumor draining lymph nodes and lungs, and enhanced overall survival outcomes. Flow cytometric analysis revealed decreased infiltration of tumor-infiltrating immunosuppressive T cells expressing the co-inhibitory markers PD-1, LAG-3, and IL-10. Furthermore, ibrutinib treatment increased cytotoxic T cell infiltration into the tumor microenvironment. Further analysis demonstrated that the effects on immunosuppressive T cell phenotypes were directly mediated by ibrutinib. Immunosuppressive myeloid cells were also observed to express lower levels of PDL1 in ibrutinib-treated mice. Our study demonstrates the potential of BTK inhibitors, specifically ibrutinib, in the treatment of HNSCC, mediated by its inhibitory effect on HNSCC cancer cell growth and metastasis, as well as modulation of the T cell anti-tumor immune microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
- Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA. oghumu.1@osu…
Förderung
- NIDA NIH HHS
- NIDCR NIH HHS
- American Cancer Society
- NIH HHS
- National Institutes of Health
Zitieren
APA
Bopp, A. R., Lamenza, F. F., Upadhaya, P., Ryan, N. M., Kazmierowicz, N., Jordanides, P. P., Siddiqui, A., Pracha, S. H., Roth, P., Iwenofu, O. H., & Oghumu, S. (2025). Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04081-5
Vancouver
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, et al. Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04081-5
BibTeX
@article{Bopp2025,
author = {Bopp, Anna R and Lamenza, Felipe F and Upadhaya, Puja and Ryan, Nathan M and Kazmierowicz, Natalie and Jordanides, Pete P and Siddiqui, Arham and Pracha, Sherefuddin H and Roth, Peyton and Iwenofu, O Hans and Oghumu, Steve},
title = {Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04081-5}
}
EUVIMED